KBC Group NV Has $2.19 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

KBC Group NV raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 78.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,972 shares of the company’s stock after buying an additional 8,332 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $2,186,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Blair William & Co. IL boosted its holdings in shares of Neurocrine Biosciences by 5.9% during the 1st quarter. Blair William & Co. IL now owns 8,599 shares of the company’s stock valued at $1,186,000 after acquiring an additional 481 shares in the last quarter. Vanguard Group Inc. raised its position in Neurocrine Biosciences by 2.3% in the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after purchasing an additional 220,598 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its stake in shares of Neurocrine Biosciences by 16.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 3,695 shares of the company’s stock valued at $510,000 after purchasing an additional 531 shares in the last quarter. UniSuper Management Pty Ltd grew its holdings in shares of Neurocrine Biosciences by 100.0% during the first quarter. UniSuper Management Pty Ltd now owns 1,400 shares of the company’s stock worth $193,000 after purchasing an additional 700 shares during the last quarter. Finally, MQS Management LLC acquired a new position in shares of Neurocrine Biosciences in the first quarter valued at approximately $551,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $117.62 on Tuesday. The stock has a 50-day moving average of $118.50 and a 200-day moving average of $132.55. Neurocrine Biosciences, Inc. has a one year low of $108.14 and a one year high of $157.98. The company has a market cap of $11.91 billion, a PE ratio of 31.53 and a beta of 0.35.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NBIX. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. Barclays decreased their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Raymond James reaffirmed an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Oppenheimer increased their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.